AMENDMENT

In the Specification

Please insert prior to the first paragraph on page 1 the following text:

"CROSS-REFERENCE TO RELATED APPLICATIONS:

[0001] This application claims the benefit of PCT Application No. PCT/AU2003/001202 (WO 2004/024947 A1) filed September, 15, 2003 which claims benefit of Australian Provisional Patent Application No. 2002951411 filed September 14, 2002. Said applications are incorporated herein by reference."

Please replace paragraph [0027] with the following rewritten paragraph:

[0027] A common polymorphism in humans has been identified in the gene encoding the skeletal muscle protein, α -actinin 3 (ACTN3) that is only present in type 2 (fast) fibers. Three possible genotypes 577RR (wildtype – expresses α -actinin-3), 577RX (heterozygous - α -actinin-3 present), and 577XX (homozygous null – no α -actinin-3 in skeletal muscle), have been identified. The allelic frequency varies in different ethnic groups (i.e. about 18% of Caucasians are α -actinin-3 deficient compared to \sim 1% of African Zulus) (see Table 3). As discussed in the Examples below, in Caucasian elite sprint/power athletes, the frequency of the 577RR genotype is very low. Thus a screening procedure for ACTN3 577XX genotype, may provide assistance in identifying for example young Caucasian individuals with potential for elite performance in sprint or power-type sports and events. In contrast, in Caucasian elite endurance athletes, the frequency of the 577XX genotype is relatively higher. Thus a screening procedure for ACTN3 577XX genotype, may also provide assistance in identifying for example young Caucasian individuals with potential for elite performance in endurance sports and events. In addition, Table 6 illustrates the genotype and allele frequencies of ACTN3 577R/X alleles in different human populations. In Table 6 and Table 2, the negroid Africans (ie Zulus) screened have an extremely low number of 577 XX individuals. Thus, the screening of ACTN3 in negroid African populations (and, likely, the related West Africans and African-Americans) to detect 577XX genotypes may prove useful in identifying individuals with sprint/power potential. In one embodiment, a method for screening for an ACTN3 allele (e.g. 577R, 577X) alone or in

combination with another screening methods may be used to select, or at least assist in the selection of, young individuals with elite sprint/power potential (e.g. potential as track sprinters, short distance swimmers, and track cyclists).